Priapism in Emergency Medicine Clinical Presentation
- Author: Colin M Dougherty, MD; Chief Editor: Robert E O'Connor, MD, MPH more...
History
- History of thromboembolic (eg, sickle cell disease) or neoplastic disease
- Drug history, including injectable medications used for erectile dysfunction such as papaverine, phentolamine, and prostaglandin E1; antipsychotic oral medications use (eg, trazodone)
- Recent illicit drug use (Cocaine, ecstasy, and marijuana use have been associated.)
- History of trauma or activities that may result in the formation of an arterial-venous fistula or shunt (eg, bicycle riding)
- Degree of pain may help to differentiate between high and low flow varieties of priapism.
- Arterial high-flow priapism
- Priapism secondary to arterial causes also may be significantly less painful than venous priapism.
- Onset of priapism may be delayed after the acute injury. The delay may be due to vessel spasm initially or to the formation of a clot that is gradually reabsorbed over a period of days.
- Priapism secondary to arterial causes usually is less tumescent when compared with venous priapism.
- Veno-occlusive priapism
- Patients with veno-occlusive priapism present with a painful erection.
- Erection may have been present for hours to days.
Physical
- Presence of priapism should be confirmed by the finding of an erect or semierect penis. The ventral glans and corpus spongiosum are rarely rigid.
- Carefully examine for evidence of trauma or unreported injection sites to the genital region.
- Examine the patient for evidence of an underlying condition that may predispose to priapism.
- Piesis sign - Perineal compression with thumb in young children causes prompt detumescence in high-flow priapism.
Causes
- Medications
- Only rare case reports of selective cyclic guanosine monophosphate (cGMP) inhibitors such as sildenafil have been associated with priapism. In fact, several case reports suggest sildenafil as a means to treat priapism and may be able to prevent full-blown episodes from occurring in patients with sickle cell disease.
- Some patients may use injectable medications to induce an erection. In these patients, excessive use may produce priapism. Examples of agents used to induce an erection include papaverine, phentolamine, and prostaglandin E1.
- Many psychotropic medications such as chlorpromazine, trazodone, quetiapine, and thioridazine have been associated with priapism. The newer agents are not immune to this complication. Priapism has been described with citalopram, a selective serotonin reuptake inhibitor.
- Rebound hypercoagulable states with anticoagulants such as heparin and warfarin have been associated. Hydralazine, metoclopramide, omeprazole, hydroxyzine, prazosin, tamoxifen, and androstenedione for athletic performance enhancement.
- Cocaine, marijuana, and ethanol abuse - The complication has been described in patients using ecstasy.[4]
- Thromboembolic
- Sickle cell disease and thalassemia
- Leukemia and multiple myeloma
- Trauma (pelvic, genital, or perineal)
- Neoplastic (may be primary or metastatic)
- Neurologic
- Spinal cord injury and anesthesia
- Cauda equina compression syndrome
- Infection
- Recent infection with Mycoplasma pneumoniae (Mechanism is thought to be a hypercoagulable state induced by the infection.)
- Malaria
- Other causes
- Fabry disease (rare association, occasionally noted to be priapism of the high-flow type) and amyloidosis
- Carbon monoxide poisoning, black widow spider bites,[5] and vigorous sexual exercise have been implicated.
- Rarely, cases of idiopathic priapism have also been reported.
Dubin J, Davis JE. Penile emergencies. Emerg Med Clin North Am. Aug 2011;29(3):485-99. [Medline].
Cherian J, Rao AR, Thwaini A, et al. Medical and surgical management of priapism. Postgrad Med J. Feb 2006;82(964):89-94. [Medline].
Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. May 2001;57(5):970-2. [Medline].
Tran QT, Wallace RA, Sim EH. Priapism, ecstasy, and marijuana: is there a connection?. Adv Urol. 2008;193694. [Medline].
Quan D, Ruha AM. Priapism associated with Latrodectus mactans envenomation. Am J Emerg Med. Jul 2009;27(6):759.e1-2. [Medline].
Bassett J, Rajfer J. Diagnostic and therapeutic options for the management of ischemic and nonischemic priapism. Rev Urol. Winter 2010;12(1):56-63. [Medline]. [Full Text].
[Guideline] Erectile Dysfunction Guideline Update Panel. The management of priapism. [reviewed and validated by AUA 2008]. Baltimore (MD): American Urological Association Inc. 2003;[Full Text].
Roberts JR, Price C, Mazzeo T. Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department. J Emerg Med. Apr 2009;36(3):285-9. [Medline].
Abern MR, Levine LA. Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol. Oct 2009;182(4):1401-6. [Medline].
Bastuba MD, Saenz de Tejada I, Dinlenc CZ, et al. Arterial priapism: diagnosis, treatment and long-term followup. J Urol. May 1994;151(5):1231-7. [Medline].
Brock G, Breza J, Lue TF, Tanagho EA. High flow priapism: a spectrum of disease. J Urol. Sep 1993;150(3):968-71. [Medline].
Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. Nov 1980;140(11):1434-7. [Medline].
Foda MM, Mahmood K, Rasuli P, Dunlap H, Kiruluta G, Schillinger JF. High-flow priapism associated with Fabry's disease in a child: a case report and review of the literature. Urology. Dec 1996;48(6):949-52. [Medline].
Harmon WJ, Nehra A. Priapism: diagnosis and management. Mayo Clin Proc. Apr 1997;72(4):350-5. [Medline].
Hatzichristou D, Salpiggidis G, Hatzimouratidis K, et al. Management strategy for arterial priapism: therapeutic dilemmas. J Urol. Nov 2002;168(5):2074-7. [Medline].
Ilkay AK, Levine LA. Conservative management of high-flow priapism. Urology. Sep 1995;46(3):419-24. [Medline].
Jiva T, Anwer S. Priapism associated with chronic cocaine abuse. Arch Intern Med. Aug 8 1994;154(15):1770. [Medline].
Lee M, Cannon B, Sharifi R. Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism. J Urol. Apr 1995;153(4):1182-3. [Medline].
Lowe FC, Jarow JP. Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Urology. Jul 1993;42(1):51-3; discussion 53-4. [Medline].
Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh PC, et al, eds. Campbell's Urology. 7th ed. Philadelphia, Pa: WB Saunders Co; 1997:1157-79.
Miller ST, Rao SP, Dunn EK, Glassberg KI. Priapism in children with sickle cell disease. J Urol. Aug 1995;154(2 Pt 2):844-7. [Medline].
Mulhall JP, Honig SC. Priapism: etiology and management. Acad Emerg Med. Aug 1996;3(8):810-6. [Medline].
Ramos CE, Park JS, Ritchey ML, Benson GS. High flow priapism associated with sickle cell disease. J Urol. May 1995;153(5):1619-21. [Medline].
Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. Nov 1993;150(5 Pt 1):1480-2. [Medline].

